PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
SOUTH PLAINFIELD, N.J., and BOSTON, M.A. – July 1, 2019 – PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therape...
About Odylia
Our Path
Resources
Consortium
What we do
Odylia Therapeutics is a non-profit corporation working to bring treatments for rare eye disease from the lab into humans using genetic therapies. Today, there are more than 300 known genetic forms of Inherited Retinal Disease (IRD) that lead to blindness, with some of these interfering with other sensory mechanisms like hearing and balance. Most are extremely rare, impacting less than one in a million people worldwide.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Latest news
Stay up-to-date with our research and clinical trials
-
-
Lara Dorfman joins Nonprofit Biotech Odylia Therapeutics
Lara Aronoff Dorfman joins Odylia Therapeutics as the Director of Business Development. Her focus for this unique ...
-
Odylia Therapeutics CEO Featured on Partners4Access Podcast
Scott Dorfman, Odylia Therapeutics CEO, was recently a featured guest on Partners4Access Weekly Podcast. A recordi...